136 related articles for article (PubMed ID: 16489005)
1. Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.
Koller E; Propp S; Zhang H; Zhao C; Xiao X; Chang M; Hirsch SA; Shepard PJ; Koo S; Murphy C; Glazer RI; Dean NM
Cancer Res; 2006 Feb; 66(4):2059-66. PubMed ID: 16489005
[TBL] [Abstract][Full Text] [Related]
2. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.
Hayashi N; Koller E; Fazli L; Gleave ME
Prostate; 2008 Sep; 68(12):1283-95. PubMed ID: 18512732
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.
Murase Y; Ono H; Ogawa K; Yoshioka R; Ishikawa Y; Ueda H; Akahoshi K; Ban D; Kudo A; Tanaka S; Tanabe M
Cancer Sci; 2021 Nov; 112(11):4641-4654. PubMed ID: 34510663
[TBL] [Abstract][Full Text] [Related]
5. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.
De Iuliis F; Taglieri L; Salerno G; Giuffrida A; Milana B; Giantulli S; Carradori S; Silvestri I; Scarpa S
Invest New Drugs; 2016 Aug; 34(4):399-406. PubMed ID: 26994617
[TBL] [Abstract][Full Text] [Related]
6. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
7. Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor.
Liu M; Yu H; Huo L; Liu J; Li M; Zhou J
Biochem Pharmacol; 2008 Jul; 76(2):169-78. PubMed ID: 18539263
[TBL] [Abstract][Full Text] [Related]
8. The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells.
Taglieri L; Rubinacci G; Giuffrida A; Carradori S; Scarpa S
Invest New Drugs; 2018 Feb; 36(1):28-35. PubMed ID: 28965307
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
11. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
12. Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.
Guido BC; Ramos LM; Nolasco DO; Nobrega CC; Andrade BY; Pic-Taylor A; Neto BA; Corrêa JR
BMC Cancer; 2015 Apr; 15():283. PubMed ID: 25885813
[TBL] [Abstract][Full Text] [Related]
13. Systemic delivery of Eg5 shRNA-expressing plasmids using PEGylated DC-Chol/DOPE cationic liposome: Long-term silencing and anticancer effects in vivo.
Seraj S; Lee J; Ahn HJ
Biochem Pharmacol; 2019 Aug; 166():192-202. PubMed ID: 31129050
[TBL] [Abstract][Full Text] [Related]
14. Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation.
Wang Y; Wu X; Du M; Chen X; Ning X; Chen H; Wang S; Liu J; Liu Z; Li R; Fu G; Wang C; McNutt MA; Zhou D; Yin Y
Oncotarget; 2017 Jun; 8(26):42510-42524. PubMed ID: 28489567
[TBL] [Abstract][Full Text] [Related]
15. Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5.
Exertier P; Javerzat S; Wang B; Franco M; Herbert J; Platonova N; Winandy M; Pujol N; Nivelles O; Ormenese S; Godard V; Becker J; Bicknell R; Pineau R; Wilting J; Bikfalvi A; Hagedorn M
Oncotarget; 2013 Dec; 4(12):2302-16. PubMed ID: 24327603
[TBL] [Abstract][Full Text] [Related]
16. Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice.
Sun Y; Lin R; Dai J; Jin D; Wang SQ
Oligonucleotides; 2006; 16(4):365-74. PubMed ID: 17155911
[TBL] [Abstract][Full Text] [Related]
17. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
[TBL] [Abstract][Full Text] [Related]
18. Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.
Ding S; Zhao Z; Sun D; Wu F; Bi D; Lu J; Xing N; Sun L; Wu H; Ding K
Tumour Biol; 2014 Aug; 35(8):7659-68. PubMed ID: 24801905
[TBL] [Abstract][Full Text] [Related]
19. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
[TBL] [Abstract][Full Text] [Related]
20. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
